A5054316857- Tuberculosis Research and Epidemiology
- Diagnosis and treatment of tuberculosis
- Pneumonia and Respiratory Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Hepatitis C virus research
- Drug Transport and Resistance Mechanisms
- Cancer therapeutics and mechanisms
- Hepatitis B Virus Studies
- Epilepsy research and treatment
- Cystic Fibrosis Research Advances
- Pharmaceutical studies and practices
- Antibiotic Resistance in Bacteria
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- Healthcare cost, quality, practices
- Biosimilars and Bioanalytical Methods
- Pharmaceutical Economics and Policy
- Pregnancy and Medication Impact
- Ion channel regulation and function
- COVID-19 and healthcare impacts
- Pharmaceutical Practices and Patient Outcomes
- Drug-Induced Hepatotoxicity and Protection
Médecins Sans Frontières
2016-2025
Médecins Sans Frontières
2018-2025
Médecins Sans Frontières
2024
Canadian Respiratory Research Network
2016
Abstract Bedaquiline is recommended by the World Health Organization for treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts patients treated with bedaquiline in France, Georgia, Armenia, South Africa a multicountry study. The rate culture conversion to negative at 6 months (by end treatment) was 78% (95% CI 73.5%–81.9%), success 65.8% 59.9%–71.3%). Death 11.7% 7.0%–19.1%). Up 91.1% 82.2%–95.8%) experienced >1 adverse...
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to completion. Evaluate safety longer MDR/RR-TB regimens containing bedaquiline and/or delamanid.Multicentre (16 countries), prospective, observational study reporting incidence and frequency clinically relevant adverse events special interest (AESIs) among patients who received delamanid. The AESIs were defined a priori as important caused by bedaquiline, delamanid, linezolid, injectables, other commonly...
Abstract Background Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative patients infected with strains TB complex drug resistance profiles or who cannot tolerate other therapies. We assessed safety treatment outcomes MDR/RR-TB receiving concomitant Bdq Dlm, along second-line anti-TB drugs. Methods conducted...
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), marketing authorization bedaquiline and delamanid was critical development in MDR-TB landscape. However, despite their availability routine programmatic use, uptake these drugs has remained slow; concerns included lack evidence on safety efficacy need protect new from acquired resistance. As part endTB Project, we aimed address barriers by generating or based...
Current recommendations for the treatment of rifampicin- and multidrug-resistant tuberculosis include bedaquiline (BDQ) used 6 months or longer. Evidence is needed to inform optimal duration BDQ.
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and patients at high risk of poor outcome.To identify unfavourable outcomes who may benefit from the new drugs.Retrospective cohort study treatment involving five 15-24 months in programmes Uzbekistan, Georgia, Armenia, Swaziland Kenya between 2001 2011.Of 1433 patients, 48.5% had body mass index (BMI) <18.5 kg/m(2),...
For the first time in almost 50 years, there are new drugs available for treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate introduction, however, has not kept pace with patient needs. It is estimated that as many 23% multidrug-resistant TB (MDR-TB) patients have an indication receiving BDQ. As this MDR-TB community introducing medications, it important to understand how implementation can be developed a variety settings.A qualitative assessment country...
Bedaquiline (BDQ) was initially only available through compassionate use programmes.To assess the effectiveness and safety of multidrug-resistant tuberculosis (MDR-TB) treatment containing BDQ.Retrospective analysis data from patients receiving BDQ in Armenia Georgia April 2013 to 2015. Logistic regression used risk factors associated with unsuccessful outcomes.Of 82 included, 84.2% (69/82) had fluoroquinolone-resistant MDR-TB 43.4% (23/53) were seropositive for hepatitis C virus (HCV). The...
Abstract Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT03259269) to estimate frequency (primary endpoint) among individuals receiving a longer (18-to-20 month) regimen for multidrug- or rifampicin-resistant (MDR/RR) TB who experienced conversion. also conduct Cox proportional hazard regression analyses identify factors associated with reversion, including...
ABSTRACT Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenian patients multidrug-resistant TB predominantly fluoroquinolone-resistant enrolled between 2013 2015 in a BDQ compassionate use program. resistance at was assessed using MGIT (pDST ), minimal inhibitory concentration 7H11 (MIC whole-genome sequencing. factors, such as effectiveness or stage of the...
BACKGROUND: The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these can be challenging in some clinical settings, incorrect classification may generate bias reporting research. Outcomes calculated by algorithms increase standardization adapted to suit the research question. We evaluated concordance between clinician-assigned treatment outcomes based on one of two algorithms, which identified failure at...
Abstract Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable outcomes. Of 31 continued pregnancies, 81% live births no reported malformations, and 68% of neonates normal birth weights. Effective MDR/RR-TB during pregnancy can improve maternal outcomes without harming neonates.
OBJECTIVE: To systematically screen older rural populations in Cambodia for tuberculosis (TB) and develop an effective active case-finding (ACF) model this TB high-risk group. DESIGN: A retrospective study using routinely collected programmatic data on community-based ACF among people aged ≥55 years symptoms systematic chest radiography (CXR) screening, followed by Xpert ® MTB/RIF testing participants with positive screening results culture certain Xpert-negative specimens. RESULTS: Of 22...
Objective We aimed to measure the prevalence and incidence of latent tuberculosis infection (LTBI) (TB) disease in children close contact with patients drug-resistant TB (DR-TB) a country high DR-TB prevalence. Design setting This is prospective cohort study paediatric contacts adult pulmonary Armenia. Children were screened using tuberculin skin test, interferon-gamma release assay chest X-ray at initial consultation, reassessed every 3–6 months for period 24 months. did not receive...
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts patients receiving delamanid as part multidrug regimen, 80% participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
Recent World Health Organization guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of agent, particularly context regimens using new repurposed drugs. We compared effectiveness an injectable-containing regimen to that among patients with who received bedaquiline and/or delamanid as part their multidrug regimen.Patients a positive baseline culture were...
INTRODUCTION: Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards surrogate to reduce TB trial duration. METHODS: We performed retrospective analysis routinely collected data in 6 drug-resistant (DRTB) programs. Culture conversion, defined as two consecutive negative cultures, was assessed, and performance culture conversion at Month 2 predict success were explored. To explore factors associated with positive predicted...